サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1512652

動物用ワクチンの世界市場：2024年～2031年

Global Veterinary Vaccines Market - 2024-2031

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
動物用ワクチンの世界市場：2024年～2031年
出版日: 2024年07月10日
発行: DataM Intelligence
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の動物用ワクチン市場は、2023年に1億2,400万米ドルに達し、2031年には2億3,600万米ドルに達すると予測され、予測期間2024-2031年のCAGRは8.4%で成長すると予測されています。

動物用ワクチンは、特定の動物疾病に対する免疫を提供する生物学的製剤です。ワクチン接種は、動物の健康状態を改善し、人獣共通感染症の蔓延を抑え、乳、肉、卵、羊毛、その他の関連製品の生産量を増加させる上で重要な役割を果たしています。

市場は、動物用ワクチンに対する政府の取り組みの増加、動物由来食品の需要の増加、家畜疾病の発生率の増加、ワクチンに対する動物の意識の高まりといった要因によって牽引されています。

市場力学：

促進要因

動物用ワクチンに関する政府の取り組みの増加

世界の動物用ワクチンの需要は、複数の要因によって牽引されています。主な要因のひとつは、動物用ワクチンに関する政府の取り組みが増加していることです。動物用ワクチンは、動物の健康や生産だけでなく、安全な食料供給を増やし、動物から人への感染症の伝播を防ぐことで、人の健康にも大きな影響を与えます。

政府機関や動物愛護団体は、様々な取り組みやプログラムを通じて動物用ワクチンの使用を積極的に推進しており、この市場の成長を後押ししています。例えば、2023年9月、FMD（口蹄疫）ワクチンプログラムの下、政府は2025年までにこの病気を封じ込め、2030年までに根絶することを意図して13,000クロー以上を計上しました。このプログラムでは、牛、水牛、羊、ヤギ、豚の100％に口蹄疫ワクチンを接種し、生後4～8ヶ月の雌子牛の100％にワクチンを接種することを目標としています。

また、2022年6月、農業・農民福祉大臣は、ハリヤナ州ヒサールにあるICAR-国立ウマ研究センターが開発した動物用ワクチンやその他の診断キットを発売しました。

さらに、動物用ワクチンを人々に認識させるための新たなプラットフォームの導入などの政府戦略は、この市場の成長を促進すると思われます。例えば、2023年6月、連邦大臣は、動物用医薬品とワクチンの申請を処理し、異議なし証明（NOC）を付与するためのNandiポータルを立ち上げました。動物用医薬品とワクチンの輸入、製造、販売の規制は、保健省傘下の中央医薬品標準管理機構（CDSCO）の管轄下にあります。

同様に、2022年8月、チャンディーガル行政局（インド）の畜産局は、パンジャブ州とハリヤナ州で牛の皮膚病が発生し、チャンディーガルからも稀な事例が報告されていることから、動物病院で予防接種を開始することを決定しました。

抑制要因

ワクチンの保管・維持コストの高さ、ワクチンに関連する副作用、厳しい規制要件、ワクチン技術の利用可能性の制限、ワクチン製造の複雑さ、動物用ワクチンの研究開発（R&D）コストの高さなどの要因が、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 動物用ワクチンに関する政府のイニシアチブの増加
      • 動物由来食品に対する需要の高まり
    • 抑制要因
      • ワクチンの保管・維持コストの高さ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • PESTEL分析
  • 特許分析
  • SWOT分析

第6章 ワクチン別

  • 家畜用ワクチン
    • 牛用ワクチン
    • 家禽用ワクチン
    • 豚用ワクチン
    • その他の家畜用ワクチン
  • コンパニオンアニマル・ワクチン
    • 犬用ワクチン
    • 猫用ワクチン
    • 馬用ワクチン

第7章 タイプ別

  • 生ワクチン
  • 不活化ワクチン
  • トキソイドワクチン
  • サブユニット
  • 組み換えワクチン
  • その他の技術

第8章 投与経路別

  • 注射ワクチン
  • 経口ワクチン
  • 経鼻／スプレーワクチン

第9章 流通チャネル別

  • 動物病院
  • 動物クリニック
  • 小売薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Merck & Co., Inc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Zoetis Services LLC
  • Boehringer Ingelheim International GmbH
  • Biogenesis Bago
  • Elanco
  • Ceva
  • HESTER BIOSCIENCES LIMITED
  • Phibro Animal Health Corporation
  • Indian Immunologicals Ltd
  • CZ Vaccines

第13章 付録

目次
Product Code: VH129

Overview

The global veterinary vaccines market reached US$ 124 million in 2023 and is expected to reach US$ 236 million by 2031, growing at a CAGR of 8.4% during the forecast period 2024-2031.

A veterinary vaccine is a biological preparation that provides immunity against a particular animal disease. Vaccination plays a crucial role in improving animal health, reducing the spread of zoonotic diseases, and increasing the production of milk, meat, eggs, wool, and other related products.

The market is driven by factors such as the increasing government initiatives for veterinary vaccines, the rising demand for animal-derived food products, the increasing incidence of livestock diseases, and the growing population of animal's awareness of vaccines.

Market Dynamics: Drivers

Increasing Government Initiatives for Veterinary Vaccines

The demand for the global veterinary vaccines market is driven by multiple factors. One of the key factors is the increasing government initiatives for veterinary vaccines. Veterinary vaccines have a major impact not only on animal health and production but also on human health through increasing safe food supplies and preventing animal-to-human transmission of infectious diseases.

Government agencies and animal welfare organizations are actively promoting the use of veterinary vaccines through various initiatives and programs to drive this market growth. For instance, in September 2023, under the FMD (Food and Mouth Disease) vaccine program, the government earmarked more than 13,000 crores intending to contain the disease by 2025 and eradicate it by 2030. The program aims to vaccinate 100% of cattle, buffalo, sheep, goat, and pig population for FMD and 100% of bovine female calves of 4-8 months of age.

Also, in June 2022, the Union Minister of Agriculture & Farmers' Welfare launched animal vaccines and other diagnostic kits developed by the ICAR-national Research Center on Equines, Hisar, Haryana.

Moreover, government strategies such as introducing new platforms to aware people of veterinary vaccines would propel this market growth. For instance, in June 2023, the Union Minister launched a Nandi portal to process applications and grant non-objection certification (NOC) for veterinary drugs and vaccines. The regulation of the import, manufacturing, and marketing of veterinary drugs and vaccines comes under the purview of the Central Drug Standard Control Organization (CDSCO) under the Ministry of Health.

Similarly, in August 2022, The Department of Animal Husbandry, Chandigarh Administration (India), has decided to start immunization in veterinary facilities because of the ongoing lumpy skin disease outbreak among cattle in Punjab and Haryana as well as rare instances being reported from Chandigarh.

Restraints

Factors such as the high storage & maintenance cost of vaccines, side-effects associated with the vaccines, stringent regulatory requirements, limited availability of vaccine technologies, complexity of vaccine manufacturing, and high cost of research and development (R&D) of veterinary vaccines are expected to hamper the market.

Segment Analysis

The global veterinary vaccines market is segmented based on the vaccine, type, route of administration, distribution channel, and region.

The canine vaccines segment accounted for approximately 56.5% of the global veterinary vaccines market share

The canine vaccines segment is expected to hold the largest market share over the forecast period. The increasing number of pet dogs globally, the growing demand for animal health care, and the increasing awareness of zoonotic diseases drive this segment's growth.

Moreover, ongoing advancements in research and development contribute to the growth of the segment. For instance, in February 2024, The University of Pennsylvania (Penn) School of Veterinary Medicine (Penn Vet) announced the launch of the school's mRNA research initiative to fast-track the development of veterinary mRNA-based vaccines and host-directed therapies.

Also, in March 2024, the Zendal group launches a CSIC-developed vaccine against canine leishmaniasis. A team formed by the Zendal group and scientists from the Spanish National Research Council developed in 2022 the first vaccine for animal mammals based on recombinant DNA to fight canine leishmaniasis, a parasite that causes from skin ulcers to severe inflammation of the liver and spleen.

In addition, key players in the market introducing the rising launches of canine vaccines help to propel this segment's growth in the market. For instance, in June 2024, MSD Animal Health announced the launch & availability of NOBIVAC NXT Rabies in Canada first-of-its-kind line of vaccines that leverages state-of-the-art RNA-particle technology to protect cats and dogs from rabies.

Also, in September 2022, Merck Animal Health announced the domestic launch of the first oral Bordetella bronchiseptica and canine parainfluenza virus vaccine with mucosal protection and easy oral administration.

Geographical Analysis

North America accounted for approximately 41.2% of the global veterinary vaccines market share

North America region is expected to hold the largest market share over the forecast period owing to the high prevalence of livestock and zoonotic diseases, rising demand for livestock-based products and animal-derived food products drives this market growth in this region.

In addition, the rising incidence of canine disorders, which is increasing the adoption of veterinary vaccination, and the rising number of pet insurance in the region are expected to propel this market growth. According to the American Pet Insurance Statistics in September 2023, in the US, 5.36 million pets are insured by their owners, in comparison to over 86.9 million pet-owning households across the country.

Moreover, key players in this region more focus on developing veterinary vaccines for infectious diseases, and government initiatives would propel this market growth. For instance, in March 2023, a joint initiative between the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), the Foreign, Commonwealth and Development Office (FCDO), and the Bill & Melinda Gates Foundation will see the creation of a new center at The Pirbright Institute designed to accelerate the development of animal vaccines to combat emerging and urgent infectious diseases.

Also, in April 2024, the United States Government, through the United States Agency for International Development (USAID), donated 100,000 doses of the anthrax vaccine in support of the Government of Ghana and the U.N. Food and Agriculture Organization's (FAO) anthrax vaccination campaign.

In addition, major players in the industry introducing newer vaccines for infectious diseases help to drive this market growth in this region, For instance, in June 2023, Boehringer Ingelheim Animal Health Canada Inc. launched a vaccine combination that delivers protection against two of the most devastating and economically damaging swine diseases in one shot. FLEX CircoPRRS protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv).

Market Segmentation

By Vaccine

  • Livestock Vaccines
    • Bovine Vaccines
    • Poultry Vaccines
    • Porcine Vaccines
    • Other Livestock Vaccines
  • Companion Animal Vaccines
    • Canine Vaccines
    • Feline Vaccines
    • Equine Vaccines

By Type

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Subunit
  • Recombinant Vaccines
  • Other Technologies

By Route of Administration

  • Injection Vaccines
  • Oral Vaccines
  • Intranasal/Spray Vaccines

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the veterinary vaccines market include Merck & Co., Inc, Zoetis Services LLC, Boehringer Ingelheim International GmbH, Biogenesis Bago, Elanco, Ceva, HESTER BIOSCIENCES LIMITED, Phibro Animal Health Corporation, Indian Immunologicals Ltd, and CZ Vaccines among others.

Key Developments

  • In March 2024, Merck Animal Health Introduces SEQUIVITY with Microsol Diluvac Forte adjuvant prescription vaccine for use in gilts and sows.
  • In October 2023, Virbac announced the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position as the animal health market leader in India by extending Virbac India's existing poultry portfolio.
  • In July 2023, Medgene introduced USDA-licensed platform vaccine technology for the cattle industry. This vaccine approach leverages USDA-approved "platform technology" guidelines that are safe, and easily adapted to multiple animal disease targets.
  • In September 2022, Merck Animal Health launched NobivacIntra-Trac Oral BbPi for the dual prevention of two major canine respiratory pathogens.
  • In August 2022, the Indian Council of Agricultural Research, ICAR-National Research Centre on Equines (ICAR-NRCE), Hisar (Haryana), in collaboration with ICAR-Indian Veterinary Research Institute (IVRI), Uttar Pradesh developed a homologous live-attenuated Lumpy Skin Disease vaccine named Lumpi-ProVacInd.

Why Purchase the Report?

  • To visualize the global veterinary vaccines market segmentation based on vaccine, type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of global veterinary vaccines market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global veterinary vaccines market report would provide approximately 70 tables, 75 figures, and 182 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Vaccine
  • 3.2. Snippet by Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Government Initiatives for Veterinary Vaccines
      • 4.1.1.2. The Rising Demand for Animal-derived Food Products
    • 4.1.2. Restraints
      • 4.1.2.1. The High Storage & Maintenance Cost of Vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Vaccine

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine
    • 6.1.2. Market Attractiveness Index, By Vaccine
  • 6.2. Livestock Vaccines *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Bovine Vaccines
    • 6.2.4. Poultry Vaccines
    • 6.2.5. Porcine Vaccines
    • 6.2.6. Other Livestock Vaccines
  • 6.3. Companion Animal Vaccines
    • 6.3.1. Canine Vaccines
    • 6.3.2. Feline Vaccines
    • 6.3.3. Equine Vaccines

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Live Attenuated Vaccines *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Inactivated Vaccines
  • 7.4. Toxoid Vaccines
  • 7.5. Subunit
  • 7.6. Recombinant Vaccines
  • 7.7. Other Technologies

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Injection Vaccines *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oral Vaccines
  • 8.4. Intranasal/Spray Vaccines

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Veterinary Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Veterinary Clinics
  • 9.4. Retail Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. UK
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co., Inc *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio & Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Zoetis Services LLC
  • 12.3. Boehringer Ingelheim International GmbH
  • 12.4. Biogenesis Bago
  • 12.5. Elanco
  • 12.6. Ceva
  • 12.7. HESTER BIOSCIENCES LIMITED
  • 12.8. Phibro Animal Health Corporation
  • 12.9. Indian Immunologicals Ltd
  • 12.10. CZ Vaccines

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us